These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12372708)

  • 1. Surprise phase III failure for ZD1839.
    Wilkinson E
    Lancet Oncol; 2002 Oct; 3(10):583. PubMed ID: 12372708
    [No Abstract]   [Full Text] [Related]  

  • 2. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
    Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
    Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
    Kelly K; Averbuch S
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR inhibitors: clinical results.
    De Marinis F; Nelli F; D'Auria G
    Suppl Tumori; 2002; 1(6):S5-6. PubMed ID: 12658893
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
    Okamoto I; Fujii K; Matsumoto M; Terasaki Y; Kihara N; Kohrogi H; Suga M
    Lung Cancer; 2003 Jun; 40(3):339-42. PubMed ID: 12781434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
    Pizzo B
    Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
    Ranson M; Thatcher N
    Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
    [No Abstract]   [Full Text] [Related]  

  • 10. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of gefitinib in lung cancer treatment.
    Giaccone G
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4233s-4237s. PubMed ID: 15217964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
    Fujiwara K; Kiura K; Ueoka H; Tabata M; Hamasaki S; Tanimoto M
    Lung Cancer; 2003 Apr; 40(1):73-6. PubMed ID: 12660009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD1839 (Iressa): what's in it for the patient?
    Natale RB; Zaretsky SL
    Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
    Ciardiello F
    Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
    [No Abstract]   [Full Text] [Related]  

  • 17. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
    Miller VA; Kris MG; Shah N; Patel J; Azzoli C; Gomez J; Krug LM; Pao W; Rizvi N; Pizzo B; Tyson L; Venkatraman E; Ben-Porat L; Memoli N; Zakowski M; Rusch V; Heelan RT
    J Clin Oncol; 2004 Mar; 22(6):1103-9. PubMed ID: 15020612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib--a novel targeted approach to treating cancer.
    Herbst RS; Fukuoka M; Baselga J
    Nat Rev Cancer; 2004 Dec; 4(12):956-65. PubMed ID: 15573117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.